On April 1, 2026, Entera Bio Ltd., a company based in Israel, announced that it has entered into a Securities Purchase Agreement with funds affiliated with BVF Partners LP. This agreement facilitates a private placement of approximately 7.83 million units, each consisting of one ordinary share and one warrant to purchase one and a half ordinary shares, for total proceeds of around $10 million. The closing of this private placement occurred on April 2, 2026. The funds raised will be utilized to support the initiation of a phase 3 registrational study of EB613, a treatment for postmenopausal women with osteoporosis, as well as for general working capital and corporate purposes. The agreement includes provisions for the issuance of pre-funded warrants, which allow the purchaser to acquire shares without exceeding a 4.99% ownership threshold unless increased to 19.99% at the holder's option. The ordinary share warrants have an exercise price of $1.24 per share and will become exercisable six months after the closing date, expiring five years from issuance. The company has committed to filing a registration statement with the SEC within 30 days to register the resale of the ordinary shares and warrants. This strategic financing is expected to enhance Entera Bio's operational capabilities and support its clinical development efforts.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.